Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.59 |
| ▸ | CCKAR | P32238 | 1/20 | 0.58 |
| ▸ | CCKBR | P32239 | 1/20 | 0.58 |
| ▸ | IL23R | Q5VWK5 | 12/20 | 0.58 |
| ▸ | GHSR | Q92847 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26247054 | 0.91 | IL23R (0.66) | IL23R | |
| SCHEMBL29496441 | 0.90 | GHSR (0.65) | GHSR | |
| SCHEMBL29496564 | 0.90 | GHSR (0.65) | GHSR | |
| SCHEMBL25037250 | 0.89 | OPRD1 (0.72) | OPRD1OPRM1CCKARCCKBRIL23R | |
| SCHEMBL25037253 | 0.89 | OPRD1 (0.72) | OPRD1OPRM1CCKARCCKBRIL23R | |
| SCHEMBL31619555 | 0.88 | GHSR (0.70) | OPRD1CCKARCCKBRGHSR | |
| SCHEMBL30365614 | 0.88 | OPRD1 (0.66) | OPRD1OPRM1CCKARCCKBR | |
| SCHEMBL30365438 | 0.88 | OPRD1 (0.68) | OPRD1OPRM1CCKARCCKBR | |
| SCHEMBL27481891 | 0.87 | KISS1R (0.60) | IL23RGHSR | |
| SCHEMBL27481890 | 0.87 | KISS1R (0.60) | IL23RGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759843-B2 | Method and pharmaceutical composition for use in the treatment of cancer | Karoyan, Philippe (FR) | 2020-09-01 | — | — | US | disclosed |
| US-20190135898-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF CANCER | PEPKON SAS (FR) | 2019-05-09 | — | — | US | disclosed |
| US-20170362302-A1 | Method and Pharmaceutical Composition for Use in the Treatment of Cancer | UNIVERSITE PARIS DIDEROT- PARIS 7 (FR) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135898-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF CANCER | KLKB1, KLK5, KLK1 | OPRD1 2159/4885OPRM1 1507/4885CCKAR 2658/4885 |
| US-20170362302-A1 | Method and Pharmaceutical Composition for Use in the Treatment of Cancer | KLKB1, KLK5, KLK1 | OPRD1 2159/4885OPRM1 1507/4885CCKAR 2658/4885 |
| US-10759843-B2 | Method and pharmaceutical composition for use in the treatment of cancer | KLKB1, KLK5, KLK1 | OPRD1 2159/4885OPRM1 1507/4885CCKAR 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.